Amneal Pharmaceuticals, Inc. Class A Common Stock Cash Flow-to-Debt Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock cash flow-to-debt ratio. Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2026, meaning its operating cash flow of $100.28 Million could theoretically repay 0% of its total liabilities ($4.63 Billion) in one year. Check Amneal Pharmaceuticals, Inc. Class A Com (AMRX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
Cash flow-to-debt ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025. Historical debt coverage capacity for Amneal Pharmaceuticals, Inc. Class A Common Stock across 11 annual periods. Check AMRX capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Amneal Pharmaceuticals, Inc. Class A Common Stock Cash Flow-to-Debt Ratio by Year (2015–2025)
Amneal Pharmaceuticals, Inc. Class A Common Stock cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Amneal Pharmaceuticals, Inc. Class A Common Stock. For the full cash flow conversion analysis, see AMRX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | $339.99 Million | $3.67 Billion | ▲ +11.2% |
| 2024 | 0.08x | $295.10 Million | $3.55 Billion | ▼ -17.9% |
| 2023 | 0.10x | $345.58 Million | $3.41 Billion | ▲ +458.7% |
| 2022 | 0.02x | $65.10 Million | $3.59 Billion | ▼ -73.2% |
| 2021 | 0.07x | $241.82 Million | $3.57 Billion | ▼ -34.8% |
| 2020 | 0.10x | $379.00 Million | $3.65 Billion | ▲ +20117.5% |
| 2019 | 0.00x | $1.71 Million | $3.32 Billion | ▼ -99.3% |
| 2018 | 0.07x | $250.23 Million | $3.46 Billion | ▼ -46.9% |
| 2017 | 0.14x | $234.19 Million | $1.72 Billion | ▲ +65.3% |
| 2016 | 0.08x | $115.06 Million | $1.39 Billion | ▼ -5.5% |
| 2015 | 0.09x | $104.88 Million | $1.20 Billion | — |